McGeer & McGeer, The future use of complement inhibitors for the treatment of neurological diseases. 55(6) Drugs 739-46 (1998). |
Morgan et al., The role of complement in disorders of the nervous systems. 38(1-2) Immunopharmacology 43-50 (1997). |
Naka et al., Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation. 64(9) Transplantation 1248-55 (1997). |
Shen et al., Characterization of neuronal cell death induced by complement activation. Brain Res Brain Res Protoc 1(2):186-94 (1997). |
Shen et al., Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain.769(2) Brain Res 391-5 (1997). |
Tao et al., Monomeric bovine IgG2 is a potent stimulus for bovine neutrophils. 58 J. Leukoc. Biol. 203-8 (1995). |
Terai et al., Neurons express proteins of the classical complement pathway in Alzheimer disease. 769(2) Brain Res 385-90 (1997). |
Gajewski et al, Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. 156(8) J. Immunol. 2909-17 (1996). |
Stabila et al., Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. 16(13) Nat Biotechnol. 1357-60 (1998). |
Yu et al., The role of B7-CD28 co-stimulation in tumor rejection. 10(6) Int. Immunol. 791-7 (1998). |